JAK
| 货号 | 产品名 | CAS号 | 信息 |
|---|---|---|---|
| FB04858 | ZM39923 | 273727-89-2 | ZM39923 is a Janus kinase inhibitor with IC50 of 10 nM. |
| FB04083 | WHI-P97 | 211555-05-4 | WHI-P97 is a rationally designed potent inhibitor of JAK-3. |
| FB05142 | Upadacitinib | 1310726-60-3 | Upadacitinib is a selective JAK1 inhibitor with an IC50 of 43 nM. |
| FB12685 | TC JL 37 | 1258294-34-6 | TCJL-37 is a potent TYK2 inhibitor. |
| FB11302 | SD1029 | 118372-34-2 | SD1029 is a cell-permeable xanthenedione compound that acts as a JAK2-selective inhibitor. |
| FB06979 | S-Ruxolitinib | 941685-37-6 | S-Ruxolitinib is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, > 130-fold selectivity for JAK1/2 versus JAK3. |
| FB02249 | Ruxolitinib Sulfate | 1092939-16-6 | Ruxolitinib sulfate is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, > 130-fold selectivity for JAK1/2 versus JAK3. |
| FB02446 | Pyridone 6 | 457081-03-7 | Pyridone 6 is a potent and selective inhibitor of JAK1 (IC50=15 nM, murine JAK1), JAK2 (IC50=1 nM), JAK3 (Ki=5 nM), and Tyk2 (IC50=1 nM) displaying significantly weaker affinities(130 nM to 10 mM) for other protein tyrosine kinases. |
| FB12422 | ZM 449829 | 4452-06-6 | Potent, selective JAK3 inhibitor |
| FB10914 | PF-956980 | 1262832-74-5 | PF-956980 is a FGF1 receptor antagonist, a PDGF receptor modulator, an Flt3 tyrosine kinase modulator, and a VEGF antagonist used as immunosuppressive agent. |
| FB17207 | PF-06826647 | 2127109-84-4 | PF-06826647 is a selective TYK2 inhibitor It is being tested in moderate-to-severe psoriasis in a Phase II clinical trial. |
| FB12771 | PF-06700841 Tosylate Salt | 2140301-96-6 | PF-06700841 P-Tosylate is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC50s of 17 nM and 23 nM, respectively. PF-06700841 P-Tosylate also inhibits JAK2 and JAK3 with IC50s of 77 nM and 6.49 μM, respectively[1]. |
| FB10926 | PF-06263276 | 1421502-62-6 | PF-06263276 is a potent and selective pan-JAK inhibitor which is suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin. |
| FB12490 | PF 06551600 Malonate | 2140301-97-7 | PF 06551600 Malonate is a potent and selective JAK3 inhibitor with IC50 of 33.1 μM. |
| FB01218 | Peficitinib | 944118-01-8 | Peficitinb is an oral Janus kinase (JAK) inhibitor. Peficitinib inhibits JAK1, JAK2, JAK3 and Tyk2 enzyme activities with IC50s of 3.9, 5.0, 0.71 and 4.8 nM, respectively, and has moderate selectivity for JAK3 inhibition. |
| FB00651 | Oclacitinib | 1208319-26-9 | Oclacitinib is a potent JAK inhibitor with IC50 value ranging in 10-99 nM for JAK family members, most potent against JAK1 with IC50 value of 10 nM. |
| FB10226 | Oclacitinib Fumarate | 1640292-55-2 | Oclacitinib Fumarate is a potent JAK inhibitor with IC50 value ranging in 10-99 nM for JAK family members, most potent against JAK1 with IC50 value of 10 nM. |
| FB00961 | NVP-BSK805 | 1092499-93-8 | NVP-BSK805 is a selective JAK2 and JAK2(V617F) mutant inhibitor with IC50 value of 0.48 nM, with >20-fold selectivity over TYK2, JAK3 and JAK1 (IC50 values of 10.8, 18.7 and 31.6 nM, respectively). |
| FB10274 | NVP-BSK805 2HCl | 1942919-79-0 | NVP-BSK805 2HCl is a potent and selective ATP-competitive JAK2 inhibitor with IC50 of 0.5 nM and > 20-fold selectivity towards JAK1, JAK3 and TYK2. |
| FB01534 | NSC 42834 | 195371-52-9 | NSC 42834, a specific inhibitor of Jak2, inhibits Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity. |
| FB12498 | NSC 33994 | 82058-16-0 | NSC 33994 is a selective inhibitor of JAK2 with IC50 of 60 nM. |
| FB10275 | NS-018 Maleate | 1354799-87-3 | NS-018 maleate is an ATP-competitive small-molecule inhibitor of JAK2 with IC50 of 470?nM in Ba/F3-JAK2V617F cells . |
| FB02404 | NS-018 | 1239358-86-1 | NS-018 is a highly selective JAK2 inhibitor. |
| FB02403 | NS-018 HCl | 1239358-85-0 | NS-018 HCl is a highly selective JAK2 inhibitor. |
| FB12732 | TCS 21311 | 1260181-14-3 | NIBR3049, also known as TCS-21311, is a potent and selective JAK3 inhibitor IC50 values of 8 nM.. |
| FB15283 | JAK3-IN-6 | 1443235-95-7 | JAK3-IN-6 is an irreversible, potent and highly selective JAK3 inhibitor with IC50 value of 0.15 nM, 4300-fold selective for JAK3 over JAK1 in enzyme assays. |
| FB04020 | JAK3-IN-1 | 1805787-93-2 | JAK3-IN-1 is a potent JAK3 inhibitor with IC50 of 4.8 nM, also inhibits JAK1 (IC50 = 896 nM) and JAK2 (IC50 = 1050 nM). |
| FB12032 | JAK-IN-1 | 1334673-53-8 | JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively. JAK-IN-1 shows improved selectivity for JAK3 over JAK1. |
| FB11192 | JAK Inhibitor C35 | 1400687-19-5 | JAK inhibitor C6 is a potent dual JAK1/3 inhibitor providing exceptional biochemical potency against JAK1 and JAK3 while maintaining good selectivity against JAK2 and Tyk2. |
| FB12031 | JAK Inhibitor 1 | 2096999-92-5 | JAK inhibitor 1 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283. |
| FB02219 | Itacitinib | 1334298-90-6 | Itacitinib is an oral selective JAK1 tyrosine kinase inhibitor, which is potential for the treatment of rheumatoid arthritis, myelofibrosis, rheumatoid arthritis and plaque psoriasis. |
| FB09946 | Itacitinib Adipate | 1334302-63-4 | Itacitinib adipate is a selective JAK1 inhibitor which has been tested for efficacy and safety in a phase II trial in myelofibrosis. |
| FB12808 | FM381 | 2226521-65-7 | FM381 is a potent covalent reversible inhibitor of JAK3 targeting the unique Cys909 at the gatekeeper position +7 in JAK3. FM-381 has an IC50 of 127 pM for JAK3, with 410, 2700 and 3600-fold selectivity over JAK1, JAK2 and TYK2, respectively. |
| FB09944 | FLLL32 | 1226895-15-3 | FLLL32 is a potent JAK2/STAT3 inhibitor with IC50 of < 5 μM. |
| FB17840 | Fedratinib hydrochloride hydrate | 1374744-69-0 | Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research. |
| FB11625 | Delgocitinib | 1263774-59-9 | Delgocitinib is a novel and specific JAK inhibitor with IC50s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively. |
| FB10875 | Debio 0617B | 1332329-27-7 | Debio 0617B is a mutiple kinase inhitor and can inhibit the growth of STAT3-Driven solid tumors through combined inhibition of JAK, SRC, and class III/V receptor tyrosine kinases.. |
| FB01973 | CYT387 Sulfate | 1056636-06-6 | CYT387 sulfate is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3. |
| FB01974 | CYT387 Mesylate | 1056636-07-7 | CYT387 mesylate is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3. |
| FB10191 | Cerdulatinib HCl | 1369761-01-2 | Cerdulatinib HCl is a dual JAK/SYK inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. It also inhibits other kinases with IC50 less than 200 nM. |
| FB16831 | BMS-986165 | 1609392-27-9 | BMS-986165 is a highly selective and allosteric TYK2 inhibitor. It is a high affinity JH2 ligand with Ki values of 0.02 nM and 1nM for binding to Tyk2 pseudokinase domain and JAK1 pseudokinase (JH2) domain, respectively. It blocked receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. |
| FB02328 | Baricitinib Phosphate | 1187595-84-1 | Baricitinib Phosphate can selectively inhibit JAK1/2 inhibitor with IC50 values of 5.9 nM and 5.7 nM. |
| FB11133 | LM-5277 | 2091134-35-7 | AZD4205 is a potent ATP-competitive inhibitor that inhibits JAK1 with a Ki of 2.8 nM and exhibits excellent selectivity compared with other JAK family kinases and across the kinome. |
| FB11818 | AZD4205 | 2091134-68-6 | AZD-4205 is a selective JAK1 inhibitor, with an IC50 of 73 nM, weakly inhibits JAK2, and shows little inhibition on JAK3 (IC50, >14.7, >30 μM, respectively). |
| FB08061 | AZ 960 | 905586-69-8 | AZ 960 is a potent ATP-competitive JAK inhibitor with IC50 values of <3 nM and 9nM for JAK2 and JAK3, respectively. |
| FB12323 | Atiprimod 2HCl | 130065-61-1 | Atiprimod 2HCl is an inhibitor JAK2 with IC50 of 397 nM. |
| FB00188 | (3S,4S)-Tofacitinib | 1092578-47-6 | (3S,4S)-Tofacitinib is an isomer of tofacitinib, an inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1. |
| FB02248 | (3S,4R)-Tofacitinib | 1092578-48-7 | (3S,4R)-Tofacitinib is an isomer of tofacitinib, which is an inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1. |
| FB00187 | (3R,4S)-Tofacitinib | 1092578-46-5 | (3R,4S)-Tofacitinib is an isomer of tofacitinib, an inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1. |
| FB00021 | Curculigoside | 85643-19-2 |